Goldman Sachs initiated Silence Therapeutics (NASDAQ:SLN) with a Sell rating and a $6 price target on Tuesday, arguing that with only about $173M of cash and equivalents at the end of Q3 2024, the U.K ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback